Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

7(77.8%)

Phase 3

1(11.1%)

N/A

1(11.1%)

9Total

Phase 2(7)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03159390Not ApplicableCompleted

Metabolism of Ornithine Phenylacetate

Role: collaborator

NCT01548690Phase 2Completed

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

Role: collaborator

NCT00867698Phase 2Completed

AST-120 Used to Treat Mild Hepatic Encephalopathy

Role: lead

NCT00583128Phase 2Completed

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Role: lead

NCT00583531Phase 2Terminated

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

Role: lead

NCT00587275Phase 2Terminated

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Role: lead

NCT00583076Phase 2Completed

Safety and Efficacy of AST-120 in the Treatment of Pouchitis

Role: lead

NCT00321412Phase 3Completed

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Role: lead

NCT00558038Phase 2Completed

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

Role: lead

All 9 trials loaded